Large effects on \BsBs mixing by vector-like quarks

We calculate the contributions of the vector-like quark model to \BsBs mixing, taking into account the constraints from the decay $B\to X_s\gamma$. In this model the neutral bosons mediate flavor-changing interactions at the tree level. However, \BsBs mixing is dominated by contributions from the box diagrams with the top quark and the extra up-type quark. In sizable ranges of the model parameters, the mixing parameter $x_s$ is much different from the standard model prediction.Comment: 11 pages, 4 figures, To be published in Phys. Rev.

Branching ratios of B+→D(∗)+K(∗)0B^+ \to D^{(*)+}K^{(*)0} decays in perturbative QCD approach

We study the rare decays $B^+ \to D^{(*)+}K^{(*)0}$, which can occur only via annihilation type diagrams in the standard model. We calculate all of the four modes, $B \to PP, VP, PV, VV$, in the framework of perturbative QCD approach and give the branching ratios of the order about $10^{-6}$.Comment: 18 pages, 1 figure, Revte

Realistic construction of split fermion models

The Standard Model flavor structure can be explained in theories where the fermions are localized on different points in a compact extra dimension. We show that models with two bulk scalars compactified on an orbifold can produce such separations in a natural way. We study the shapes and overlaps of the fermion wave functions. We show that, generically, realistic models of Gaussian overlaps are unnatural since they require very large Yukawa couplings between the fermions and the bulk scalars. We give an example of a five dimensional two scalar model that accounts naturally for the observed quark masses, mixing angles and CP violation.Comment: 15 pages, 5 figures, typos corrected, discussion on the implications of SM rare decay processes added, to appear in PR

Rare Charm Decays in the Standard Model and Beyond

We perform a comprehensive study of a number of rare charm decays, incorporating the first evaluation of the QCD corrections to the short distance contributions, as well as examining the long range effects. For processes mediated by the $c\to u\ell^+\ell^-$ transitions, we show that sensitivity to short distance physics exists in kinematic regions away from the vector meson resonances that dominate the total rate. In particular, we find that $D\to\pi\ell^+\ell^-$ and $D\to\rho\ell^+\ell^-$ are sensitive to non-universal soft-breaking effects in the Minimal Supersymmetric Standard Model with R-parity conservation. We separately study the sensitivity of these modes to R-parity violating effects and derive new bounds on R-parity violating couplings. We also obtain predictions for these decays within extensions of the Standard Model, including extensions of the Higgs, gauge and fermion sectors, as well as models of dynamical electroweak symmetry breaking.Comment: 45 pages, typos fixed, discussions adde

The Three Families from SU(4)A⊗SU(3)C⊗SU(2)L⊗U(1)XSU(4)_A\otimes SU(3)_C\otimes SU(2)_L\otimes U(1)_X SM-like Chiral Models

We give a detailed description of the model construction procedures about our new approach to the family structure of the standard model. SM-like chiral fermion spectra, largely "derivable" from the gauge anomaly constraints, are formulated in a $SU(N)\otimes SU(3)\otimes SU(2)\otimes U(1)$ symmetry framework as an extension of the SM symmetry. The $N=4$ case gives naturally three families as a result, with $U(1)_Y$ nontrivially embedded into the $SU(4)_A\otimes U(1)_X$. Such a spectrum has extra vector-like quarks and leptons. We illustrate how an acceptable symmetry breaking pattern can be obtained through a relatively simple scalar sector which gives naturally hierarchical quark mass matrices. Compatibility with various FCNC constraints and some interesting aspects of the possible phenomenological features are discussed, from a non-model specific perspective. The question of incorporating supersymmetry without putting in the Higgses as extra supermultiplet is also addressed.Comment: 43 pages RevTex, including 9 tables and 3 figure

GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide hits reported for SSc thus far. We define 95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify specific SSc subtype-associated signals. Functional analysis of high-priority variants shows the potential function of SSc signals, with the identification of 43 robust target genes through HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for the disease. This work supports a better understanding of the genetic basis of SSc and provides directions for future functional experiments

Search for B⁺c decays to the pp‾π⁺ final state

A search for the decays of the B + c meson to pp-π + is performed for the first time using a data sample corresponding to an integrated luminosity of 3.0 fb -1 collected by the LHCb experiment in pp collisions at centre-of-mass energies of 7 and 8 TeV. No signal is found and an upper limit, at 95% confidence level, is set, fcfu×B(B + c →ppπ + ) < 3.6×10-8 in the kinematic region m(pp) < 2.85 GeV/c2, p T (B) < 20 GeV/c and 2.0 < y(B) < 4.5, where B is the branching fraction and f c (f u ) is the fragmentation fraction of the b quark into a B c + (B + ) meson

New insights into the genetic etiology of Alzheimer's disease and related dementias

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele

Measurement of the lifetime of the Bc+B_c^+ meson using the Bc+→J/ψπ+B_c^+\rightarrow J/\psi\pi^+ decay mode

The difference in total widths between the $B_c^+$ and $B^+$ mesons is measured using 3.0fb$^{-1}$ of data collected by the LHCb experiment in 7 and 8 TeV centre-of-mass energy proton-proton collisions at the LHC. Through the study of the time evolution of $B_c^+ \rightarrow J/\psi \pi^+$ and $B^+\rightarrow J/\psi K^+$ decays, the width difference is measured to be $$\Delta\Gamma \equiv \Gamma_{B_c^+} - \Gamma_{B^+} = 4.46 \pm 0.14 \pm 0.07mm^{-1}c,$$ where the first uncertainty is statistical and the second systematic. The known lifetime of the $B^+$ meson is used to convert this to a precise measurement of the $B_c^+$ lifetime, $$\tau_{B_c^+} = 513.4 \pm 11.0 \pm 5.7fs,$$ where the first uncertainty is statistical and the second systematic.Comment: 19 pagers, 3 figure

Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema : Subgroup analysis of the MEAD study

Background: Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) was approved for treatment of diabetic macular edema (DME) after demonstration of its efficacy and safety in the MEAD registration trials. We performed subgroup analysis of MEAD study results to evaluate the efficacy and safety of DEX 0.7 treatment in patients with previously treated DME. Methods: Three-year, randomized, sham-controlled phase 3 study in patients with DME, best-corrected visual acuity (BCVA) of 34.68 Early Treatment Diabetic Retinopathy Study letters (20/200.20/50 Snellen equivalent), and central retinal thickness (CRT) 65300 \u3bcm measured by time-domain optical coherence tomography. Patients were randomized to 1 of 2 doses of DEX (0.7 mg or 0.35 mg), or to sham procedure, with retreatment no more than every 6 months. The primary endpoint was 6515-letter gain in BCVA at study end. Average change in BCVA and CRT from baseline during the study (area-under-the-curve approach) and adverse events were also evaluated. The present subgroup analysis evaluated outcomes in patients randomized to DEX 0.7 (marketed dose) or sham based on prior treatment for DME at study entry. Results: Baseline characteristics of previously treated DEX 0.7 (n = 247) and sham (n=261) patients were similar. In the previously treated subgroup, mean number of treatments over 3 years was 4.1 for DEX 0.7 and 3.2 for sham, 21.5 % of DEX 0.7 patients versus 11.1 % of sham had 6515-letter BCVA gain from baseline at study end (P = 0.002), mean average BCVA change from baseline was +3.2 letters with DEX 0.7 versus +1.5 letters with sham (P = 0.024), and mean average CRT change from baseline was -126.1 \u3bcm with DEX 0.7 versus -39.0 \u3bcm with sham(P < 0.001). Cataract-related adverse events were reported in 70.3 % of baseline phakic patients in the previously treated DEX 0.7 subgroup; vision gains were restored following cataract surgery. Conclusions: DEX 0.7 significantly improved visual and anatomic outcomes in patients with DME previously treated with laser, intravitreal anti-vascular endothelial growth factor, intravitreal triamcinolone acetonide, or a combination of these therapies. The safety profile of DEX 0.7 in previously treated patients was similar to its safety profile in the total study population